RY3
SUSMi001-A
General
Cell Line |
|
| hPSCreg name | SUSMi001-A |
| Cite as: | SUSMi001-A (RRID:CVCL_UM29) |
| Alternative name(s) |
RY3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi001-B (FB78R2c2, CENSOi249) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi002-B (FB74R2c4, CENSOi261) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy LUBi001-A (PGRN-8310, PGRN8310, RCi195, RCFB58 c12.5) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia LUBi001-B (PGRN-8310, RCFB58 c4.4, PGRN8310, RCi194) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia LUBi001-C (PGRN-8310, RCFB58 c3.7, RCi200, PGRN8310) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia STBCi110-A (SFC116-03-01) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UCLi004-A (RCi173, RCFB60c6) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-B (RCFB60c7, RCi177) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-C (RCi172, RCFB60c2) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | Stanford University School of Medicine (SUSM) |
External Databases |
|
| BioSamples | SAMEA4909539 |
| Cellosaurus | CVCL_UM29 |
| Wikidata | Q98132883 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
| Subclones | |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA4909540 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent | |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Details on restriction to research project | |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Please describe how access is provided: | |
| Contact data, institution, or website: | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | University of California San Francisco Institutional Review Board |
| Approval number | 13-10806 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | University of California San Francisco Institutional Review Board |
| Approval number | 13-10806 |
| Please describe: | |
| Further constraints on use | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution |
hIPSC Derivation
General |
|
| Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
| Source cell origin |
A zone of skin that is part of a back [Automatically generated definition].; EDITOR_NOTE TODO - distinguish between entire skin of region and arbitrary zone of skin on region
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
Yes |
| Notes on reprogramming vector detection | Southern Blot |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
normal
Passage number: 20
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.